Novartis AG
Change company Symbol lookup
Select an option...
NVS Novartis AG
UNM Unum Group
LLY Eli Lilly and Co
BDC Belden Inc
TTM Tata Motors Ltd
HOG Harley-Davidson Inc
SKY Skyline Champion Corp
MPX Marine Products Corp

Health Care : Pharmaceuticals | Large Cap Value
Based in Switzerland
Company profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company's range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Day's Change
-2.07 (-2.56%)
B/A Size
Day's High
Day's Low
(Heavy Day)

Today's volume of 452,444 shares is on pace to be much greater than NVS's 10-day average volume of 1,640,966 shares.


UPDATE: Under Armour stock falls after updated restructuring plan includes increased charges

3:53 pm ET September 9, 2020 (MarketWatch)

By Tonya Garcia

Under Armour Inc. (UAA)(UAA) stock fell nearly 3% in Wednesday trading after the athletic company announced an updated restructuring plan that includes higher charges.

"After further review, the Company has identified further opportunities and on September 2, 2020, the Company's Board of Directors approved a $75 million increase to the restructuring plan, resulting in an updated 2020 restructuring plan of approximately $550 million to $600 million of total estimated pre-tax restructuring and related charges," Under Armour said in a corporate filing.

The plan also includes 600 job cuts, which comes with a $30 million charge for benefits and severance. In February (, Under Armour announced a plan that had the potential for $325 million to $425 million in pretax charges. That included $225 million to $250 million for an abandoned New York City flagship.

Under Armour says the majority of the charges will be incurred by the end of 2020. By June 30, the company had tallied $340 million in charges.

"Strong buy-rated Under Armour continues to take prudent steps to restructure the business during unprecedented times and position the story for clean, profitable growth in 2021 and beyond," wrote Raymond James analysts in a note.

Under Armour stock has been halved over the year to date, down 50.8%, while the S&P 500 index is up almost 6% for the period.

-Tonya Garcia; 415-439-6400;

(END) Dow Jones Newswires

September 09, 2020 15:53 ET (19:53 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.